Iovance Historical Income Statement

IOVA Stock

USD 10.01 0.25 2.44%

Historical analysis of Iovance Biotherapeutics income statement accounts such as Selling General Administrative of 30.7 M or Other Operating Expenses of 484.8 M can show how well Iovance Biotherapeutics performed in making a profits. Evaluating Iovance Biotherapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Iovance Biotherapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Iovance Biotherapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Iovance Biotherapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iovance Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.

About Iovance Income Statement Analysis

Iovance Biotherapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Iovance Biotherapeutics shareholders. The income statement also shows Iovance investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Iovance Biotherapeutics Income Statement Chart

Iovance Biotherapeutics Income Statement is one of the three primary financial statements used for reporting Iovance's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Iovance Biotherapeutics revenue and expense. Iovance Biotherapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.

At present, Iovance Biotherapeutics' Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 3.6 M, whereas Operating Income is projected to grow to (437.5 M).

Selling General Administrative Other Operating Expenses Total Operating Expenses Research Development Reconciled Depreciation

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Iovance Biotherapeutics. It is also known as Iovance Biotherapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Iovance Biotherapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Iovance Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iovance Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.At present, Iovance Biotherapeutics' Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 3.6 M, whereas Operating Income is projected to grow to (437.5 M).

	2021	2022	2023	2024 (projected)
Net Interest Income	451K	3.0M	11.6M	12.2M
Interest Income	451K	3.0M	11.6M	12.2M

Net Interest Income Interest Income

Iovance Biotherapeutics income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Ebit	Ebitda	Total Operating Expenses	Income Before Tax	Net Income	Total Other Income Expense Net	Income Tax Expense	Gross Profit	Net Income From Continuing Ops	Research Development	Cost Of Revenue	Non Recurring	Non Operating Income Net Other	Interest Income	Net Interest Income	Reconciled Depreciation	Selling And Marketing Expenses
Depreciation And Amortization		0.79	0.4	0.9	-0.89	-0.89	-0.87	0.88	-0.88	-0.89	0.59	-0.39	-0.81	-0.88	0.89	0.83	-0.83	-0.04	0.74	0.74	1.0	-0.83
Interest Expense	0.79		0.37	0.75	-0.74	-0.74	-0.73	0.74	-0.74	-0.75	0.61	-0.15	-0.68	-0.75	0.74	0.7	-0.66	-0.14	0.58	0.58	0.79	-0.66
Selling General Administrative	0.4	0.37		0.68	-0.7	-0.7	-0.72	0.71	-0.71	-0.71	-0.03	-0.68	-0.26	-0.72	0.68	0.24	0.03	0.22	0.15	0.11	0.44	0.03
Other Operating Expenses	0.9	0.75	0.68		-1.0	-1.0	-1.0	1.0	-1.0	-1.0	0.54	-0.6	-0.69	-1.0	1.0	0.71	-0.66	0.2	0.75	0.73	0.9	-0.66
Operating Income	-0.89	-0.74	-0.7	-1.0		1.0	1.0	-1.0	1.0	1.0	-0.52	0.61	0.68	1.0	-1.0	-0.69	0.62	-0.21	-0.73	-0.71	-0.89	0.62
Ebit	-0.89	-0.74	-0.7	-1.0	1.0		1.0	-1.0	1.0	1.0	-0.52	0.61	0.68	1.0	-1.0	-0.69	0.62	-0.21	-0.73	-0.71	-0.89	0.62
Ebitda	-0.87	-0.73	-0.72	-1.0	1.0	1.0		-1.0	1.0	1.0	-0.51	0.62	0.66	1.0	-1.0	-0.67	0.6	-0.23	-0.73	-0.7	-0.87	0.6
Total Operating Expenses	0.88	0.74	0.71	1.0	-1.0	-1.0	-1.0		-1.0	-1.0	0.51	-0.62	-0.67	-1.0	1.0	0.69	-0.63	0.22	0.73	0.7	0.88	-0.63
Income Before Tax	-0.88	-0.74	-0.71	-1.0	1.0	1.0	1.0	-1.0		1.0	-0.5	0.61	0.68	1.0	-1.0	-0.69	0.61	-0.2	-0.72	-0.7	-0.88	0.61
Net Income	-0.89	-0.75	-0.71	-1.0	1.0	1.0	1.0	-1.0	1.0		-0.5	0.6	0.68	1.0	-1.0	-0.69	0.62	-0.2	-0.72	-0.7	-0.89	0.62
Total Other Income Expense Net	0.59	0.61	-0.03	0.54	-0.52	-0.52	-0.51	0.51	-0.5	-0.5		-0.19	-0.33	-0.49	0.54	0.37	-0.67	0.44	0.79	0.79	0.57	-0.67
Income Tax Expense	-0.39	-0.15	-0.68	-0.6	0.61	0.61	0.62	-0.62	0.61	0.6	-0.19		0.23	0.62	-0.61	-0.22	0.1	-0.39	-0.29	-0.27	-0.4	0.1
Gross Profit	-0.81	-0.68	-0.26	-0.69	0.68	0.68	0.66	-0.67	0.68	0.68	-0.33	0.23		0.69	-0.68	-1.0	0.68	0.36	-0.59	-0.6	-0.81	0.68
Net Income From Continuing Ops	-0.88	-0.75	-0.72	-1.0	1.0	1.0	1.0	-1.0	1.0	1.0	-0.49	0.62	0.69		-1.0	-0.7	0.6	-0.18	-0.71	-0.69	-0.88	0.6
Research Development	0.89	0.74	0.68	1.0	-1.0	-1.0	-1.0	1.0	-1.0	-1.0	0.54	-0.61	-0.68	-1.0		0.69	-0.65	0.23	0.75	0.73	0.88	-0.65
Cost Of Revenue	0.83	0.7	0.24	0.71	-0.69	-0.69	-0.67	0.69	-0.69	-0.69	0.37	-0.22	-1.0	-0.7	0.69		-0.73	-0.34	0.62	0.63	0.84	-0.73
Non Recurring	-0.83	-0.66	0.03	-0.66	0.62	0.62	0.6	-0.63	0.61	0.62	-0.67	0.1	0.68	0.6	-0.65	-0.73		0.04	-0.78	-0.79	-0.8	1.0
Non Operating Income Net Other	-0.04	-0.14	0.22	0.2	-0.21	-0.21	-0.23	0.22	-0.2	-0.2	0.44	-0.39	0.36	-0.18	0.23	-0.34	0.04		0.4	0.39	-0.06	0.04
Interest Income	0.74	0.58	0.15	0.75	-0.73	-0.73	-0.73	0.73	-0.72	-0.72	0.79	-0.29	-0.59	-0.71	0.75	0.62	-0.78	0.4		1.0	0.71	-0.78
Net Interest Income	0.74	0.58	0.11	0.73	-0.71	-0.71	-0.7	0.7	-0.7	-0.7	0.79	-0.27	-0.6	-0.69	0.73	0.63	-0.79	0.39	1.0		0.7	-0.79
Reconciled Depreciation	1.0	0.79	0.44	0.9	-0.89	-0.89	-0.87	0.88	-0.88	-0.89	0.57	-0.4	-0.81	-0.88	0.88	0.84	-0.8	-0.06	0.71	0.7		-0.8
Selling And Marketing Expenses	-0.83	-0.66	0.03	-0.66	0.62	0.62	0.6	-0.63	0.61	0.62	-0.67	0.1	0.68	0.6	-0.65	-0.73	1.0	0.04	-0.78	-0.79	-0.8

Click cells to compare fundamentals

Iovance Biotherapeutics Account Relationship Matchups

Iovance Biotherapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	1.2M	1.1M	14.0M	21.1M	33.1M	34.8M
Selling General Administrative	40.8M	60.2M	83.7M	104.1M	27.7M	30.7M
Other Operating Expenses	206.9M	261.9M	342.7M	398.9M	461.7M	484.8M
Operating Income	(206.9M)	(261.9M)	(342.7M)	(398.9M)	(460.6M)	(437.5M)
Ebit	(206.9M)	(261.9M)	(342.7M)	(398.9M)	(460.6M)	(437.5M)
Ebitda	(205.7M)	(260.8M)	(328.7M)	(377.7M)	(427.4M)	(406.1M)
Total Operating Expenses	206.9M	261.9M	342.7M	398.9M	428.6M	450.1M
Income Before Tax	(197.6M)	(259.6M)	(342.3M)	(395.9M)	(447.5M)	(425.1M)
Net Income	(187.1M)	(257.2M)	(327.8M)	(389.9M)	(444.0M)	(421.8M)
Total Other Income Expense Net	9.3M	2.4M	451K	3.0M	13.0M	13.7M
Income Tax Expense	(10.5M)	(2.4M)	(14.4M)	(6.0M)	(3.5M)	(3.3M)
Gross Profit	(8.1M)	(8.7M)	(14.0M)	(21.1M)	(31.9M)	(30.3M)
Net Income From Continuing Ops	(197.6M)	(259.6M)	(342.3M)	(395.9M)	(433.0M)	(411.3M)
Research Development	166.0M	201.7M	259.0M	294.8M	344.1M	361.3M
Cost Of Revenue	8.1M	8.7M	14.0M	21.1M	33.1M	34.8M
Non Operating Income Net Other	4.7M	9.3M	2.4M	451K	518.7K	492.7K
Net Income Applicable To Common Shares	(197.6M)	(259.6M)	(342.3M)	(395.9M)	(356.3M)	(338.5M)
Interest Income	9.3M	2.4M	451K	3.0M	11.6M	12.2M
Net Interest Income	9.3M	2.4M	451K	3.0M	11.6M	12.2M
Reconciled Depreciation	1.2M	1.1M	14.0M	21.1M	29.1M	30.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

MSFT	Microsoft
GM	General Motors
CRM	Salesforce

When determining whether Iovance Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Iovance Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Iovance Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Iovance Biotherapeutics Stock:

How To Invest In Iovance

Details

Is Iovance Stock a good investment?

Details

What is Iovance Biotherapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.

You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Complementary Tools for Iovance Stock analysis

When running Iovance Biotherapeutics' price analysis, check to measure Iovance Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iovance Biotherapeutics is operating at the current time. Most of Iovance Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Iovance Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iovance Biotherapeutics' price. Additionally, you may evaluate how the addition of Iovance Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Transaction History View history of all your transactions and understand their impact on performance
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon

Is Iovance Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. If investors know Iovance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iovance Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.81)

Revenue Per Share

0.008

Return On Assets

(0.34)

Return On Equity

(0.67)

The market value of Iovance Biotherapeutics is measured differently than its book value, which is the value of Iovance that is recorded on the company's balance sheet. Investors also form their own opinion of Iovance Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iovance Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iovance Biotherapeutics' market value can be influenced by many factors that don't directly affect Iovance Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iovance Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Iovance Historical Income Statement

About Iovance Income Statement Analysis

Iovance Biotherapeutics Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Iovance Biotherapeutics income statement Correlations

Iovance Biotherapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Iovance Biotherapeutics income statement Accounts

Also Currently Popular

Complementary Tools for Iovance Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Reconciled Depreciation	+ 1.0	Depreciation And Amortization
Total Operating Expenses	+ 1.0	Other Operating Expenses
Research Development	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income

Research Development	- 1.0	Net Income From Continuing Ops
Cost Of Revenue	- 1.0	Gross Profit
Research Development	- 1.0	Net Income
Research Development	- 1.0	Income Before Tax
Net Income From Continuing Ops	- 1.0	Total Operating Expenses
Net Income	- 1.0	Total Operating Expenses